vs

Side-by-side financial comparison of Bally's Corp (BALY) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Bally's Corp is the larger business by last-quarter revenue ($746.2M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -47.3%, a 81.8% gap on every dollar of revenue. On growth, Bally's Corp posted the faster year-over-year revenue change (28.6% vs 4.8%). Over the past eight quarters, Bally's Corp's revenue compounded faster (9.8% CAGR vs 4.6%).

Bally's Corporation is an American gambling, betting, and interactive entertainment company headquartered in Providence, Rhode Island. In the US it operates 19 casinos across 11 states, a horse track in Colorado, a golf course in New York, and online sports betting operations in 14 states. In Australia, it operates two properties across two states through its Star Entertainment Group subsidiary.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BALY vs RPRX — Head-to-Head

Bigger by revenue
BALY
BALY
1.2× larger
BALY
$746.2M
$622.0M
RPRX
Growing faster (revenue YoY)
BALY
BALY
+23.8% gap
BALY
28.6%
4.8%
RPRX
Higher net margin
RPRX
RPRX
81.8% more per $
RPRX
34.4%
-47.3%
BALY
Faster 2-yr revenue CAGR
BALY
BALY
Annualised
BALY
9.8%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BALY
BALY
RPRX
RPRX
Revenue
$746.2M
$622.0M
Net Profit
$-353.2M
$214.2M
Gross Margin
Operating Margin
-36.8%
62.4%
Net Margin
-47.3%
34.4%
Revenue YoY
28.6%
4.8%
Net Profit YoY
-311.8%
2.9%
EPS (diluted)
$-5.84
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BALY
BALY
RPRX
RPRX
Q4 25
$746.2M
$622.0M
Q3 25
$663.7M
$609.3M
Q2 25
$657.5M
$578.7M
Q1 25
$368.7M
$568.2M
Q4 24
$580.4M
$593.6M
Q3 24
$630.0M
$564.7M
Q2 24
$621.7M
$537.3M
Q1 24
$618.5M
$568.0M
Net Profit
BALY
BALY
RPRX
RPRX
Q4 25
$-353.2M
$214.2M
Q3 25
$-102.9M
$288.2M
Q2 25
$-228.4M
$30.2M
Q1 25
$34.5M
$238.3M
Q4 24
$-85.8M
$208.2M
Q3 24
$-247.9M
$544.0M
Q2 24
$-60.2M
$102.0M
Q1 24
$-173.9M
$4.8M
Operating Margin
BALY
BALY
RPRX
RPRX
Q4 25
-36.8%
62.4%
Q3 25
0.1%
70.1%
Q2 25
-0.4%
36.3%
Q1 25
-0.5%
94.0%
Q4 24
-5.6%
60.9%
Q3 24
-25.0%
Q2 24
0.9%
50.2%
Q1 24
-12.0%
-13.0%
Net Margin
BALY
BALY
RPRX
RPRX
Q4 25
-47.3%
34.4%
Q3 25
-15.5%
47.3%
Q2 25
-34.7%
5.2%
Q1 25
9.4%
41.9%
Q4 24
-14.8%
35.1%
Q3 24
-39.3%
96.3%
Q2 24
-9.7%
19.0%
Q1 24
-28.1%
0.8%
EPS (diluted)
BALY
BALY
RPRX
RPRX
Q4 25
$-5.84
$0.49
Q3 25
$-1.70
$0.67
Q2 25
$-3.76
$0.07
Q1 25
$0.57
$0.55
Q4 24
$-1.76
$0.46
Q3 24
$-5.10
$1.21
Q2 24
$-1.24
$0.23
Q1 24
$-3.61
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BALY
BALY
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$798.4M
$618.7M
Total DebtLower is stronger
$4.5B
$9.0B
Stockholders' EquityBook value
$994.7M
$9.7B
Total Assets
$11.2B
$19.6B
Debt / EquityLower = less leverage
4.52×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BALY
BALY
RPRX
RPRX
Q4 25
$798.4M
$618.7M
Q3 25
$160.7M
$938.9M
Q2 25
$174.6M
$631.9M
Q1 25
$209.7M
$1.1B
Q4 24
$171.2M
$929.0M
Q3 24
$191.0M
$950.1M
Q2 24
$154.7M
$1.8B
Q1 24
$169.4M
$843.0M
Total Debt
BALY
BALY
RPRX
RPRX
Q4 25
$4.5B
$9.0B
Q3 25
$3.7B
$8.9B
Q2 25
$3.6B
$8.0B
Q1 25
$3.5B
$7.6B
Q4 24
$3.3B
$7.6B
Q3 24
$3.7B
$7.6B
Q2 24
$3.7B
$7.6B
Q1 24
$3.7B
$6.1B
Stockholders' Equity
BALY
BALY
RPRX
RPRX
Q4 25
$994.7M
$9.7B
Q3 25
$521.5M
$9.6B
Q2 25
$630.1M
$9.5B
Q1 25
$796.5M
$9.8B
Q4 24
$30.9M
$10.3B
Q3 24
$233.4M
$10.3B
Q2 24
$393.1M
$9.8B
Q1 24
$449.4M
$9.9B
Total Assets
BALY
BALY
RPRX
RPRX
Q4 25
$11.2B
$19.6B
Q3 25
$7.6B
$19.3B
Q2 25
$7.8B
$18.3B
Q1 25
$7.5B
$17.6B
Q4 24
$5.9B
$18.2B
Q3 24
$6.4B
$18.0B
Q2 24
$6.6B
$17.7B
Q1 24
$6.6B
$16.1B
Debt / Equity
BALY
BALY
RPRX
RPRX
Q4 25
4.52×
0.92×
Q3 25
7.17×
0.93×
Q2 25
5.68×
0.84×
Q1 25
4.33×
0.78×
Q4 24
107.40×
0.74×
Q3 24
15.73×
0.74×
Q2 24
9.34×
0.78×
Q1 24
8.19×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BALY
BALY
RPRX
RPRX
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
5.1%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BALY
BALY
RPRX
RPRX
Q4 25
$827.1M
Q3 25
$-88.6M
$702.6M
Q2 25
$364.0M
Q1 25
$42.0M
$596.1M
Q4 24
$37.8M
$742.5M
Q3 24
$36.5M
$703.6M
Q2 24
$47.6M
$658.2M
Q1 24
$-7.9M
$664.6M
Free Cash Flow
BALY
BALY
RPRX
RPRX
Q4 25
Q3 25
$-139.3M
Q2 25
Q1 25
$11.5M
Q4 24
$-5.9M
Q3 24
$-55.8M
Q2 24
$11.8M
Q1 24
$-35.9M
FCF Margin
BALY
BALY
RPRX
RPRX
Q4 25
Q3 25
-21.0%
Q2 25
Q1 25
3.1%
Q4 24
-1.0%
Q3 24
-8.9%
Q2 24
1.9%
Q1 24
-5.8%
Capex Intensity
BALY
BALY
RPRX
RPRX
Q4 25
5.1%
Q3 25
7.6%
Q2 25
7.4%
Q1 25
8.3%
Q4 24
7.5%
Q3 24
14.7%
Q2 24
5.7%
Q1 24
4.5%
Cash Conversion
BALY
BALY
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
1.22×
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BALY
BALY

Casinos Resorts$366.2M49%
Non Casino$172.7M23%
Food And Beverage$74.6M10%
Hotel$69.9M9%
North America Interactive$62.3M8%
Loyalty Programs$6.7M1%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons